Jérôme Tamburini
Reproducibility track record
1
assessed papers
32/100
mean reproducibility
0
reproduced (C1–C2)
1
flagged
0
total citations
flag rate:
100%
(1/1)
The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.
Authorship role
first author: 0
last author: 0
Topics
Funders
—
Frequent co-authors
Guilhem Clary 1Elissa Khadra 1Didier Bouscary 1Justine Decroocq 1Charles Dussiau 1Morgane Le Gall 1Michaëla Fontenay 1Nicolas Chapuis 1Zubaidan Tuerdi 1Françoise Levavasseur 1
Institutions
Centre National de la Recherche Scientifique 1Inserm 1Université Paris Cité 1Institut Cochin 1Acute Leukemia French Association 1Fondation pour la Recherche Médicale 1
Geography (author institutions)
FR 1DE 1CH 1
Co-author network
Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.
How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.
Assessed papers (1)
Complete publication record (392)
Request a reproduction →1 assessed by us (0 reproduced) · 391 not yet assessed — every PubMed paper on record, linked below.
-
Azacitidine-induced remission enables allogeneic transplantation in <i>TET2</i>/<i>BCOR</i>-mutant relapsed extranodal natural killer/T-cell lymphoma: a case report ↗Haematologica · 2026 · PMID 41924921not yet assessed
-
Targeting ferritinophagy to iron out <i>Tet2</i>-mutant cells ↗Blood · 2025 · PMID 40906503not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia⚑Communications Biology · 2025 · PMID 41407883L1 32/100 ⚑
-
Selective haematological cancer eradication with preserved haematopoiesis ↗Nature · 2024 · PMID 38778101not yet assessed
-
Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models ↗Science Translational Medicine · 2024 · PMID 39047119not yet assessed
-
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation ↗Leukemia · 2024 · PMID 39187579not yet assessed
-
Maternal and obstetric outcomes in women with pregnancy-associated haematological malignancies: an observational nationwide cohort study ↗The Lancet Haematology · 2024 · PMID 39389070not yet assessed
-
The E3 ubiquitin ligase MARCH5 promotes mitochondrial fusion and cell-cycle progression in acute myeloid leukemia ↗Blood Advances · 2024 · PMID 39471482not yet assessed
-
Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive <scp>B‐</scp>cell lymphoma: Insights from real‐life clinical practice ↗Cancer Reports · 2024 · PMID 39410860not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
C/EBPα Confers Dependence to Fatty Acid Anabolic Pathways and Vulnerability to Lipid Oxidative Stress–Induced Ferroptosis in <i>FLT3</i> -Mutant Leukemia ↗Cancer Discovery · 2023 · PMID 37012202not yet assessed
-
Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia ↗Leukemia · 2023 · PMID 36739349not yet assessed
-
Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy ↗The Journal of Experimental Medicine · 2023 · PMID 37773046not yet assessed
-
Identification of a miRNA multi-targeting therapeutic strategy in glioblastoma ↗Cell Death and Disease · 2023 · PMID 37749143not yet assessed
-
AMPK activation induces immunogenic cell death in AML ↗Blood Advances · 2023 · PMID 37903311not yet assessed
-
Very short insertions in the <i>FLT3</i> gene are of therapeutic significance in acute myeloid leukemia ↗Blood Advances · 2023 · PMID 37987760not yet assessed
-
Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study ↗Annals of Hematology · 2023 · PMID 36991231not yet assessed
-
Ferroptose, métabolisme lipidique, C/EBPα et résistance thérapeutique dans les leucémies aiguës myéloïdes ↗médecine/sciences · 2023 · PMID 38108717not yet assessed
-
Tandem versus single haematopoietic stem cell transplant and <scp>BV</scp> maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the <scp>LYSA</scp> ↗British Journal of Haematology · 2023 · PMID 37192755not yet assessed
-
Clinico‐biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi‐centric observational study ↗British Journal of Haematology · 2023 · PMID 37403204not yet assessed
-
SCD inhibition preferentially eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy ↗bioRxiv (Cold Spring Harbor Laboratory) · 2023not yet assessed
-
not yet assessed
-
Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study ↗Haematologica · 2023 · PMID 36994502not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
Ferritinophagy is a Druggable Vulnerability of Quiescent Leukemic Stem Cells ↗bioRxiv (Cold Spring Harbor Laboratory) · 2023not yet assessed
-
not yet assessed
-
AMPK-PERK axis represses oxidative metabolism and enhances apoptotic priming of mitochondria in acute myeloid leukemia ↗Cell Reports · 2022 · PMID 34986346not yet assessed
-
At the crossroads of fertility and metabolism: the importance of AMPK-dependent signaling in female infertility associated with hyperandrogenism ↗Human Reproduction · 2022 · PMID 35459945not yet assessed
-
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia ↗Leukemia · 2022 · PMID 35354920not yet assessed
-
Accuracy and safety of 101 consecutives neurosurgical procedures for newly diagnosed central nervous system lymphomas: a single-institution experience ↗Journal of Neuro-Oncology · 2022 · PMID 35759152not yet assessed
-
T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients ↗Annals of Oncology · 2022 · PMID 36116692not yet assessed
-
C/EBPα confers dependence to fatty acid anabolic pathways and vulnerability to lipid oxidative stress in FLT3-mutant leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2022not yet assessed
-
P1357: IMPAIRED CELLULAR RESPONSES AGAINST SARS-COV-2 AFTER COVID-19 INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS ↗HemaSphere · 2022not yet assessed
-
Mitochondrial Fusion Supports Proliferation of Leukemia-Initiating Cells Through mTORC1 in Patient-Derived Xenograft Models ↗SSRN Electronic Journal · 2022not yet assessed
-
not yet assessed
-
not yet assessed
-
not yet assessed
-
APR-246 induces early cell death by ferroptosis in acute myeloid leukemia ↗Haematologica · 2021 · PMID 33406814not yet assessed
-
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia ↗Nature Cancer · 2021 · PMID 35122057not yet assessed
-
Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells ↗Nature Communications · 2021 · PMID 33462236not yet assessed
-
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma ↗Blood · 2021 · PMID 34905598not yet assessed
-
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia ↗Leukemia & lymphoma/Leukemia and lymphoma · 2021 · PMID 34405773not yet assessed
-
Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study ↗Haematologica · 2021 · PMID 34965701not yet assessed
-
AMP-Activated Protein Kinase Contributes to Apoptosis Induced by the Bcl-2 Inhibitor Venetoclax in Acute Myeloid Leukemia ↗Cancers · 2021 · PMID 34885077not yet assessed
-
AMAHRELIS : ADCETRIS MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA : A REAL LIFE STUDY FROM SFGMTC AND LYSA GROUPS ↗Hematological Oncology · 2021not yet assessed
-
not yet assessed
-
not yet assessed
-
Management and outcome of primary CNS lymphoma in the modern era ↗Neurology · 2020 · PMID 31907289not yet assessed
-
Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endoplasmic reticulum contact sites ↗Nature Communications · 2020 · PMID 32792483not yet assessed
-
Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML ↗European Journal Of Haematology · 2020 · PMID 32659848not yet assessed
-
Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia ↗Cancer Discovery · 2020 · PMID 32641297not yet assessed
-
Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow ↗Cell Reports · 2020 · PMID 31968250not yet assessed
-
Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia ↗Oncogenesis · 2020 · PMID 33093450not yet assessed
-
Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin ↗Bone Marrow Transplantation · 2020 · PMID 31959893not yet assessed
-
IgA monoclonal gammopathy associated with refractory IgA vasculitis successfully treated with clone-targeted therapy ↗Autoimmunity Reviews · 2020 · PMID 32659477not yet assessed
-
not yet assessed
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) ↗UNC Libraries · 2020not yet assessed
-
Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy ↗Leukemia & lymphoma/Leukemia and lymphoma · 2020 · PMID 32856491not yet assessed
-
An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML ↗bioRxiv (Cold Spring Harbor Laboratory) · 2020not yet assessed
-
Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells ↗bioRxiv (Cold Spring Harbor Laboratory) · 2020not yet assessed
-
Mitochondrial determinants of response and resistance to venetoclax <i>plus</i> cytarabine duplet therapy in acute myeloid leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2020not yet assessed
-
Adrenomedullin-CALCRL Axis Controls Relapse-Initiating Drug Tolerant Acute Myeloid Leukemia Cells ↗Research Square · 2020not yet assessed
-
Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML ↗Leukemia · 2020 · PMID 32665699not yet assessed
-
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements ↗Blood · 2019 · PMID 31434701not yet assessed
-
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? ↗Blood Advances · 2019 · PMID 31869411not yet assessed
-
AMPK Activation Promotes Tight Junction Assembly in Intestinal Epithelial Caco-2 Cells ↗International Journal of Molecular Sciences · 2019 · PMID 31635305not yet assessed
-
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia ↗Frontiers in Oncology · 2019 · PMID 31192118not yet assessed
-
Evidence for IL-35 Expression in Diffuse Large B-Cell Lymphoma and Impact on the Patient's Prognosis ↗Frontiers in Oncology · 2019 · PMID 31316915not yet assessed
-
RETRACTED ARTICLE: LAMP2 expression dictates azacytidine response and prognosis inMDS/AML ↗Leukemia · 2019 · PMID 30607021not yet assessed
-
Autologous<sup>111</sup>Indium‐oxinate‐labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor‐agonists ↗British Journal of Haematology · 2019 · PMID 30950041not yet assessed
-
High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah’s Witnesses patients: a feasible option in the age of hematopoietic growth factors ↗Leukemia & lymphoma/Leukemia and lymphoma · 2019 · PMID 30773115not yet assessed
-
Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study ↗British Journal of Haematology · 2019 · PMID 31215036not yet assessed
-
Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia ↗bioRxiv (Cold Spring Harbor Laboratory) · 2019not yet assessed
-
not yet assessed
-
Sinusoidal Obstruction Syndrome: Warning About Autologous Stem Cell Transplantation Preceded by Regimens Containing Oxaliplatin ↗Clinical Lymphoma Myeloma & Leukemia · 2019not yet assessed
-
not yet assessed
-
Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia ↗Haematologica · 2018 · PMID 30262561not yet assessed
-
Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients ↗Haematologica · 2018 · PMID 29472354not yet assessed
-
Finely-tuned regulation of AMP-activated protein kinase is crucial for human adult erythropoiesis ↗Haematologica · 2018 · PMID 30309849not yet assessed
-
A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia ↗Oncotarget · 2018 · PMID 29682194not yet assessed
-
Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients ↗Oncotarget · 2018 · PMID 29682187not yet assessed
-
Urgent Chemotherapy in Sepsis-Like Shock Related to Hematologic Malignancies ↗Critical Care Medicine · 2018 · PMID 29373361not yet assessed
-
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a <scp>LYSA</scp> study ↗British Journal of Haematology · 2018 · PMID 29611187not yet assessed
-
T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization ↗Haematologica · 2018 · PMID 30573508not yet assessed
-
Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia ↗Clinical Chemistry and Laboratory Medicine (CCLM) · 2018 · PMID 30267623not yet assessed
-
Proton beam therapy for the management of mediastinal Hodgkin lymphoma in a young female patient ↗Cancer/Radiothérapie · 2018 · PMID 29606542not yet assessed
-
Aplastic Anemia in the Elderly: A Nationwide Survey on Behalf of the French Reference Center for Aplastic Anemia ↗Blood · 2018not yet assessed
-
not yet assessed
-
Quel est le rôle de l’AMPK dans le maintien de l’homéostasie de la barrière intestinale ?2018not yet assessed
-
High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells ↗Leukemia · 2017 · PMID 28280275not yet assessed
-
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study ↗Bone Marrow Transplantation · 2017 · PMID 28436974not yet assessed
-
Indications and outcome of splenectomy in hematologic disease ↗Journal of Visceral Surgery · 2017 · PMID 28757383not yet assessed
-
RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia ↗Leukemia · 2017 · PMID 28914261not yet assessed
-
S100 proteins in AML: differentiation and beyond ↗Blood · 2017 · PMID 28385770not yet assessed
-
Indications et résultats de la splénectomie dans les pathologies hématologiques ↗Journal de Chirurgie Viscérale · 2017not yet assessed
-
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy ↗Leukemia & lymphoma/Leukemia and lymphoma · 2017 · PMID 29087212not yet assessed
-
Proceedings of Réanimation 2017, the French Intensive Care Society International Congress ↗Annals of Intensive Care · 2017not yet assessed
-
Spinal cord involvement in a Burkitt lymphoma patient ↗Cancer Reports and Reviews · 2017not yet assessed
-
Abstract 4087: Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies ↗Cancer Research · 2017not yet assessed
-
Iconography : Indications and outcome of splenectomy in hematologic disease2017not yet assessed
-
Inactivation of AMPK in human granulosa cellsHAL (Le Centre pour la Communication Scientifique Directe) · 2017not yet assessed
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) ↗Autophagy · 2016 · PMID 26799652not yet assessed
-
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice ↗Cancer Cell · 2016 · PMID 27070704not yet assessed
-
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice ↗Cancer Cell · 2016not yet assessed
-
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for<i>FLT3</i><i>-</i>ITD acute myeloid leukemia ↗Science Translational Medicine · 2016 · PMID 27708062not yet assessed
-
Efficacy and long‐term toxicity of the rituximab‐fludarabine‐cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia ↗American Journal of Hematology · 2016 · PMID 27135784not yet assessed
-
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies ↗Leukemia & lymphoma/Leukemia and lymphoma · 2016 · PMID 27118302not yet assessed
-
Polyserositis in the course of chronic myelomonocytic leukemia: impact of hypomethylating agents ↗Cancer Research Frontiers · 2016not yet assessed
-
not yet assessed
-
Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition ↗Blood · 2015 · PMID 26186940not yet assessed
-
Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells ↗Blood · 2015 · PMID 26286850not yet assessed
-
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia ↗Cell Reports · 2015 · PMID 26004183not yet assessed
-
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia ↗Science Advances · 2015 · PMID 26601252not yet assessed
-
Antileukemic Activity of 2-Deoxy- <scp>d</scp> -Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with <i>FLT3-ITD</i> or <i>c-KIT</i> Mutations ↗Molecular Cancer Therapeutics · 2015 · PMID 26206337not yet assessed
-
Autologous hematopoietic stem cell transplantation in elderly patients (≥70years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study ↗Journal of Geriatric Oncology · 2015 · PMID 26116168not yet assessed
-
CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia ↗Oncotarget · 2015 · PMID 26515730not yet assessed
-
Control of Pim2 kinase stability and expression in transformed human haematopoietic cells ↗Bioscience Reports · 2015 · PMID 26500282not yet assessed
-
not yet assessed
-
MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis ↗Haematologica · 2015 · PMID 26206803not yet assessed
-
Co-activation of AMPK and mTORC1 as a new therapeutic option for acute myeloid leukemia ↗Molecular & Cellular Oncology · 2015 · PMID 27652311not yet assessed
-
PET<sub>2</sub>‐driven de‐escalation therapy in 64 high‐risk Hodgkin Lymphoma patients treated with escalated BEACOPP ↗British Journal of Haematology · 2015 · PMID 25580881not yet assessed
-
Frontline Clofarabine and Cytarabine combination for plasmocytoid blastic dendritic cell neoplasm ↗Cancer Research Frontiers · 2015not yet assessed
-
Coactivation d’AMPK et de mTORC1 ↗médecine/sciences · 2015 · PMID 26481022not yet assessed
-
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance ↗Nature Medicine · 2014 · PMID 25485910not yet assessed
-
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup ↗Blood · 2014 · PMID 25006122not yet assessed
-
Rituximab therapy for hairy cell leukemia: a retrospective study of 41 cases ↗Annals of Hematology · 2014 · PMID 25195120not yet assessed
-
Targeting CHK1 inhibits cell proliferation in FLT3-ITD positive acute myeloid leukemia ↗Leukemia Research · 2014 · PMID 25281057not yet assessed
-
GNB1 Activating Mutations Promote Myeloid and Lymphoid Neoplasms Targetable By Combined PI3K/mTOR Inhibition ↗Blood · 2014not yet assessed
-
not yet assessed
-
not yet assessed
-
Use of Signaling Pathways as Therapeutic Targets for Blood Cancer ↗International Journal of Hematologic Oncology · 2014not yet assessed
-
not yet assessed
-
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia ↗Blood · 2013 · PMID 24014241not yet assessed
-
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse ↗Leukemia · 2013 · PMID 23321953not yet assessed
-
Antileukaemic effect of <scp>PI</scp>3<scp>K</scp>‐m<scp>TOR</scp> inhibitors in acute myeloid leukaemia‐gene expression profiles reveal <scp>CDC</scp>25<scp>B</scp> expression as determinate of pharmacological effect ↗British Journal of Haematology · 2013 · PMID 24383842not yet assessed
-
Successful treatment of<scp>l</scp>-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors ↗Leukemia & lymphoma/Leukemia and lymphoma · 2013 · PMID 24090500not yet assessed
-
Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia ↗Leukemia · 2013 · PMID 23748345not yet assessed
-
Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support ↗British Journal of Haematology · 2013 · PMID 23480574not yet assessed
-
Predicting effects of kinase inhibitor in therapy for myeloid malignancies – the challenges in capturing disease heterogeneity ↗Expert Opinion on Investigational Drugs · 2013 · PMID 24099404not yet assessed
-
Profound anaemia and acute blindness in a Jehovah's Witness ↗The Lancet · 2013 · PMID 24034299not yet assessed
-
Chronic myelomonocytic leukemia associated with generalized myasthenia gravis ↗Leukemia & lymphoma/Leukemia and lymphoma · 2013 · PMID 24050508not yet assessed
-
Rituximab For Hairy-Cell Leukemia (HCL): A Multicentric Retrospective Study Of 41 Cases ↗Blood · 2013not yet assessed
-
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies ↗Current Oncology Reports · 2012 · PMID 22350330not yet assessed
-
Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature ↗Leukemia & lymphoma/Leukemia and lymphoma · 2012 · PMID 22385269not yet assessed
-
The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction ↗British Journal of Cancer · 2012 · PMID 22510748not yet assessed
-
The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells ↗Blood · 2012 · PMID 22343664not yet assessed
-
Sustained Leukemia-Free State and Molecular Response to Sorafenib in a Patient With Chronic Myelomonocytic Leukemia in Transformation Driven by Homozygous FLT3-ITD Malignant Hematopoiesis ↗Clinical Lymphoma Myeloma & Leukemia · 2012 · PMID 23246161not yet assessed
-
not yet assessed
-
not yet assessed
-
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study ↗Haematologica · 2011 · PMID 21933861not yet assessed
-
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia ↗Leukemia · 2011 · PMID 22143671not yet assessed
-
Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy ↗Haematologica · 2011 · PMID 21228037not yet assessed
-
LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology ↗Cell Cycle · 2011 · PMID 21572254not yet assessed
-
Leukemic phase of follicular lymphomas: an atypical presentation ↗Leukemia & lymphoma/Leukemia and lymphoma · 2011 · PMID 21585282not yet assessed
-
Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia ↗Haematologica · 2011 · PMID 21393333not yet assessed
-
Focal Rituximab-Induced Edematous Reaction at Primary Cutaneous Follicle Center Lymphoma Lesions: Case Report and Literature Review ↗Dermatology · 2011 · PMID 21986026not yet assessed
-
Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing non‐Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim ↗British Journal of Haematology · 2011 · PMID 21848881not yet assessed
-
The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia ↗British Journal of Haematology · 2011 · PMID 21995271not yet assessed
-
not yet assessed
-
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation ↗Blood · 2010 · PMID 20668229not yet assessed
-
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia ↗Clinical Cancer Research · 2010 · PMID 20884625not yet assessed
-
Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies ↗Leukemia · 2010 · PMID 20703258not yet assessed
-
IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia ↗Blood · 2010 · PMID 20671123not yet assessed
-
Feasibility of Helical Tomotherapy for Debulking Irradiation Before Stem Cell Transplantation in Malignant Lymphoma ↗International Journal of Radiation Oncology*Biology*Physics · 2010 · PMID 20646850not yet assessed
-
Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination ↗Leukemia & lymphoma/Leukemia and lymphoma · 2010 · PMID 20929331not yet assessed
-
Insulin Receptor A and IGF-1R in AML – Letter ↗Cancer Research · 2010 · PMID 20699367not yet assessed
-
Fludarabine Plus Cyclophosphamide and Rituximab In Waldenstrom's Macroglobulinemia: Results In 55 Patients ↗Blood · 2010not yet assessed
-
not yet assessed
-
R88: Impact du nombre de cellules leucémiques chimiorésistantes CD34+CD38-CD123+ sur la réponse au traitement et la survie de patients atteints de leucémie aiguë myéloïde ↗Bulletin du Cancer · 2010not yet assessed
-
R45: Metformine comme traitement adjuvant de la leucémie aiguë myéloïde ↗Bulletin du Cancer · 2010not yet assessed
-
Targeted inhibition of mtor by azd8055 blocks protein translation and has anti-leukemic activity in acute myeloid leukemiaHAL (Le Centre pour la Communication Scientifique Directe) · 2010not yet assessed
-
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia ↗Haematologica · 2009 · PMID 19951971not yet assessed
-
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia ↗Blood · 2009 · PMID 19458359not yet assessed
-
Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody ↗Haematologica · 2009 · PMID 20007139not yet assessed
-
Targeting translation in acute myeloid leukemia: A new paradigm for therapy? ↗Cell Cycle · 2009 · PMID 19934662not yet assessed
-
Balancing Risk Versus Benefit in the Treatment of Waldenström's Macroglobulinemia Patients with Nucleoside Analogue–Based Therapy ↗Clinical Lymphoma & Myeloma · 2009 · PMID 19362978not yet assessed
-
Helical Tomotherapy for Debulking Irradiation Prior to Stem Cells Transplantation in Malignant Lymphoma ↗International Journal of Radiation Oncology*Biology*Physics · 2009not yet assessed
-
not yet assessed
-
IκB Kinase Overcomes PI3K to Control FoxO3a Subcellular Localization in Acute Myeloid Leukemia. ↗Blood · 2009not yet assessed
-
P111 Long-term outcome of MDS with del 5q before the lenalidomide era. The GFM experience ↗Leukemia Research · 2009not yet assessed
-
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML ↗Leukemia · 2008 · PMID 18548104not yet assessed
-
Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy ↗Leukemia & lymphoma/Leukemia and lymphoma · 2008 · PMID 18720213not yet assessed
-
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes ↗Leukemia Research · 2008 · PMID 18640718not yet assessed
-
Autocrine IGF-1/IGF-1R Signaling Is Responsible for PI3K/Akt Constitutive Activation in Acute Myeloid Leukemia. ↗Blood · 2008not yet assessed
-
Protein Synthesis Escapes mTORC1 Control and Constitutes a Promising Therapeutic Target in Acute Myeloid Leukemia. ↗Blood · 2008not yet assessed
-
mTORC1 Activity Is Independent of PI3K/Akt but Controlled by AMPK in Acute Myeloid Leukemia. ↗Blood · 2008not yet assessed
-
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways ↗Blood · 2007 · PMID 17878402not yet assessed
-
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia ↗American Journal of Respiratory and Critical Care Medicine · 2007 · PMID 17600277not yet assessed
-
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients ↗Blood · 2007 · PMID 17426258not yet assessed
-
Cytokine pattern in Kaposi's sarcoma associated with immune restoration disease in HIV and tuberculosis co-infected patients ↗AIDS · 2007 · PMID 17721110not yet assessed
-
not yet assessed
-
not yet assessed
-
Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. ↗PubMed · 2006 · PMID 16769577not yet assessed
-
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype ↗Leukemia · 2006 · PMID 16791266not yet assessed
-
Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia. ↗Blood · 2006not yet assessed
-
Low Doses of Thalidomide (Thal) in Low Risk MDS with Transfusion-Dependant Anemia: The GFM THAL-SMD-200 Trial. ↗Blood · 2006not yet assessed
-
not yet assessed
-
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients ↗Leukemia · 2005 · PMID 16121217not yet assessed
-
Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110δ mutations ↗Leukemia · 2005 · PMID 16341041not yet assessed
-
Listeria monocytogenes Meningitis Following Imatinib Mesylate-Induced Monocytopenia in a Patient with Chronic Myeloid Leukemia ↗Clinical Infectious Diseases · 2005 · PMID 16267747not yet assessed
-
Acute bacterial meningitis in a patient receiving ibuprofen ↗Journal of Infection · 2004 · PMID 16291288not yet assessed
-
Interactions between cyclophosphamide and doxorubicin metabolism in rats. II. Effect of cyclophosphamide on the aldoketoreductase system. ↗Journal of Pharmacology and Experimental Therapeutics · 1986 · PMID 3514847not yet assessed
-
Comparative anthracycline metabolism in rats: loss of marcellomycin fluorescence. ↗PubMed · 1986 · PMID 3084076not yet assessed
-
Interactions between cyclophosphamide and adriamycin metabolism in rats. ↗Journal of Pharmacology and Experimental Therapeutics · 1984 · PMID 6423814not yet assessed
-
The murine metabolism and disposition of marcellomycin. ↗Drug Metabolism and Disposition · 1984 · PMID 6144487not yet assessed
Full bibliography from OpenAlex; reproducibility verdicts matched by PMID.
Author attribution follows OpenAlex disambiguation, which is imperfect — a researcher's papers can be split across profiles or mixed with a namesake.
Merged across profiles sharing this ORCID where present. See every “Tamburini J” paper on PubMed ↗